Page 7 - Angle Plc News Today

/PRNewswire/ -- The Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline report is expected to rise due to an increased prevalence rate of...

Investegate announcements from Angle PLC, Exercise of options and total voting rights

Angle losses widen in H1 on increased investment spend

26 April 2021 | 09:20am StockMarketWire.com - Liquid biopsy company Angle said it had completed patient enrolment for its ovarian cancer clinical verification study, with headline results expected in the fourth quarter of 2021. The study would support the launch of an ovarian cancer test from Angles clinical laboratories in the United States and the UK. The study is designed to evaluate the use of Angles Parsortix system for circulating tumour cell harvest and subsequent downstream analysis wit...

Headline results are expected in the fourth quarter, investors were told Angle PLC (LON:AGL, OTCQX:ANPCY) said it completed the patient enrolment of 200 women for its ovarian cancer clinical verification study. Scientists and doctors from the University of Rochester Medical Center, New York, will assess the ability of the company’s Parsortix system to detect the presence of ovarian cancer in women with a pelvic mass prior to surgery. The liquid biopsy system will be used to harvest circu...

16 April 2021 | 07:54am StockMarketWire.com - Liquid biopsy company Angle said it had won its first pharma services contract worth $1.2 million over 18 months with scope for further contracts from the same customer. The customer would use the companys parsortix system in cancer drug trials for liquid biopsy longitudinal monitoring. The work related to a phase 3 prostate cancer study and two smaller phase I studies. The phase I studies, if successful, could progress to larger phase II studies ...

About ANGLE plc   www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood te...

Share this article Share this article ResearchAndMarkets.coms offering. The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted). Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising fo...

4 March 2021 | 10:11am StockMarketWire.com - Liquid biopsy company Angle said it was likely that US clearance for Parsortix would occur later than initially expected after the company received a request to supply further information from the US Food and Drug Administration. The company said it was likely clearance would occur in the second half of 2021 rather than the previous guidance of the "earliest prospect of FDA clearance being Q2 CY21". Some of the technical information requested n...

About ANGLE plc www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix ® system, and it enables a liquid biopsy (a simple b...